ArticleInternational journal of molecular sciences2015
The Safety Evaluation of Salvianolic Acid B and Ginsenoside Rg1 Combination on Mice.
Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Mechanisms of salvianolic acids in kidney disease therapy: advances and perspectives.Frontiers in pharmacology · 2026Review
- The "habitat-phytochemistry-pharmacological effect" nexus: a multidimensional review of ethnomedicinalFrontiers in pharmacology · 2026Review
- Salvianolic acid B: a promising cardioprotective agent.Frontiers in immunology · 2025Review
- CAP2 promotes gastric cancer metastasis by mediating the interaction between tumor cells and tumor-associated macrophages.The Journal of clinical investigation · 2023Article
- Identifying Crude Drugs in Kampo Medicines Associated with Drug-Induced Liver Injury Using the Japanese Adverse Drug Event Report Database: A Comprehensive Survey.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Improved up-and-down procedure for acute toxicity measurement with reliable LDBMC pharmacology & toxicology · 2022Article
- Natural products: potential treatments for cisplatin-induced nephrotoxicity.Acta pharmacologica Sinica · 2021Review
- Effect of ginsenoside-Rg1 on experimental Parkinson's disease: A systematic review and meta-analysis of animal studies.Experimental and therapeutic medicine · 2021Article
- Ginsenoside Rg1 promotes lymphatic drainage and improves chronic inflammatory arthritis.Journal of musculoskeletal & neuronal interactions · 2020Article
- Possible applications of salvianolic acid B against different cancers.Exploration of targeted anti-tumor therapy · 2020Review
- Ginsenoside Rg1 ameliorates the cognitive deficits in D-galactose and AlClInternational journal of medical sciences · 2020Article
- Salvianolic acid A & B: potential cytotoxic polyphenols in battle against cancer via targeting multiple signaling pathways.International journal of biological sciences · 2019Review
- Ginseng for Liver Injury: Friend or Foe?Medicines (Basel, Switzerland) · 2016Review
- Salvianolic Acid B Ameliorates Cerebral Ischemia/Reperfusion Injury Through Inhibiting TLR4/MyD88 Signaling Pathway.Inflammation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our previous study indicated that the combination of salvianolic acid B (SalB) and ginsenoside Rg1 (Rg1), the main components of Salvia miltiorrhizae and Panax notoginseng, improves myocardium structure and ventricular function in rats with ischemia/reperfusion injury. The present study aimed to determine the safety of the combined SalB and Rg1 (SalB-Rg1) in mice. The safety of SalB-Rg1 was evaluated through acute toxicity and repeated-dose toxicity. In the acute toxicity study, the up and down procedure was carried out firstly, and then, the Bliss method was applied. In the toxicity study for seven-day repeated treatment of SalB-Rg1, forty Kunming mice were randomly divided into four groups. The intravenous median lethal dose (LD50) of the SalB-Rg1 combination was 1747 mg/kg using the Bliss method. For both the acute toxicity study and the seven-day repeated toxicity study, SalB-Rg1 did not induce significant abnormality on brain, heart, kidney, liver and lung structure at any dose based on H&E stain. There were no significant changes related to the SalB-Rg1 toxicity detected on biochemical parameters for two kinds of toxicity studies. The LD50 in mice was 1747 mg/kg, which was more than one hundred times higher than the effective dose. Both studies of acute toxicity and seven-day repeated dose toxicity indicated the safety of the SalB-Rg1 combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.